PAI
ACHN

ProQuest Associates IV’s Achillion Pharmaceuticals ACHN Stock Holding History

ProQuest Associates IV’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,122,957
Closed -$13.8M – 7
2014
Q4 		$13.8M Buy
+1,122,957
New +$13.7M 6.97% 4

Other funds holding ACHN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ProQuest Associates IV's ACHN Position: Q1 2015 in Review

ProQuest Associates IV sold out of Achillion Pharmaceuticals (ACHN) in Q1 2015, closing a stake of 1,122,957 shares — an estimated $13.8M sold.

ProQuest Associates IV first reported a position in ACHN in Q4 2014 and held it in 1 quarter. The position peaked at $13.8M in Q4 2014. 173 funds tracked by Wall St. Rank hold ACHN as of Q1 2015.

  • ProQuest Associates IV reported no remaining Achillion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • ProQuest Associates IV sold 1,122,957 Achillion Pharmaceuticals shares in Q1 2015, an estimated $13.8M.
  • ProQuest Associates IV first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • ProQuest Associates IV's Achillion Pharmaceuticals position peaked at $13.8M in Q4 2014.
  • 173 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2015.

Based on ProQuest Associates IV's 13F filing for Q1 2015, filed 15 May 2015.